Cassava Sciences Inc. (Nasdaq: SAVA) saw its stock jump by 8.6% in early trading after announcing the completion of dosing in the ReTHINK Phase 3 clinical trial, which included 804 patients. This milestone marks a significant step forward in the development of simufilam, the company’s leading Alzheimer’s drug candidate.
Alongside the clinical update, Cassava’s settlement with the SEC further cleared the path for simufilam’s continued development. This agreement also follows internal governance changes, which aim to bolster the company’s operational integrity amid heightened scrutiny.
Cassava Sciences has been a key player in the biotech sector, particularly with its focus on addressing Alzheimer’s disease through innovative treatments. With the completion of the ReTHINK trial, investors are optimistic about the future prospects of simufilam, and this reflects in the company’s strong stock performance today.
This recent surge puts Cassava Sciences on the radar of investors as they await further updates on the efficacy and safety results of the trial.